Safety

GLP-1 and Cancer Risk: Separating Facts from Fears

GLP-1 Companion · 8 min read

When a patient reads the prescribing information for a GLP-1 medication and encounters warnings about thyroid tumors and pancreatic cancer, fear is a rational response. But the full scientific picture requires understanding where those warnings come from, what 20 years of real-world human data actually show, and how those risks stack up against the well-established cancer risk of obesity itself.

The Thyroid C-Cell Warning: Rodent Data, Not Replicated in Humans

Every GLP-1 receptor agonist carries an FDA black box warning about thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). The warning originates from mandatory two-year carcinogenicity studies in rodents, where GLP-1 drugs caused dose-dependent C-cell hyperplasia and MTC across multiple species. This is a class effect tied to GLP-1 receptor activation on rodent thyroid C-cells.

Critically, rodents express GLP-1 receptors on thyroid C-cells at 7–10 times the density found in humans. Non-human primate studies — far more physiologically relevant — showed no C-cell abnormalities even at high doses. After nearly 20 years of human use (exenatide was approved in 2005), no major epidemiological study or pharmacovigilance analysis has confirmed an increased incidence of MTC in GLP-1 users. The SELECT trial (n=17,604, median 3.3 years on semaglutide 2.4 mg) found no significant increase in any thyroid cancer subtype.

The Pancreatic Cancer Question

Concern about pancreatic cancer arose in the early 2010s when case reports of pancreatitis and pancreatic neoplasia in GLP-1 users prompted regulatory scrutiny. The FDA and EMA conducted joint reviews in 2013 and found the available data insufficient to establish a causal link. Subsequent large-scale investigations have been reassuring.

• The LEADER trial (liraglutide vs placebo, n=9,340) found no significant difference in pancreatic cancer incidence between treatment groups over a median 3.8 years.
• SUSTAIN-6 and SUSTAIN-7 trials for semaglutide reported no elevated pancreatic cancer signal.
• A 2019 pooled analysis of GLP-1 cardiovascular outcomes trials covering more than 55,000 patient-years found no statistically significant increase in pancreatic cancer versus comparators.
• Large observational database studies using insulin as an active comparator have found hazard ratios close to 1.0 for pancreatic cancer, with confidence intervals that do not reach significance.

There remains a theoretical biologic concern because GLP-1 receptors are expressed on pancreatic ductal and acinar cells, and pancreatitis is a known albeit rare side effect. However, the population-level epidemiological data — now spanning millions of patient-years — do not support a clinically meaningful elevation in pancreatic cancer risk.

Obesity as a Major Modifiable Cancer Risk Factor

To fully evaluate GLP-1 and cancer risk, the baseline must be acknowledged: obesity is itself one of the most significant modifiable cancer risk factors known. The International Agency for Research on Cancer (IARC) has identified excess body weight as a cause of at least 13 distinct cancer types, including postmenopausal breast cancer, endometrial cancer, colorectal cancer, kidney cancer, liver cancer, gallbladder cancer, esophageal adenocarcinoma, ovarian cancer, and thyroid cancer (the papillary and follicular subtypes, not MTC).

The American Cancer Society estimates that approximately 11% of all cancers in the United States in women and 5% in men are attributable to excess body weight. The mechanisms are multiple: adipose tissue-driven chronic inflammation, elevated estrogen from peripheral aromatization, insulin resistance and hyperinsulinemia, elevated IGF-1, and adipokine dysregulation all contribute to a pro-oncogenic milieu.

Potential Protective Effect of Weight Loss

If obesity drives cancer risk through the mechanisms listed above, weight loss should logically reduce that risk over time — and emerging data support this. Bariatric surgery studies, which provide the longest follow-up for significant weight loss, have demonstrated reduced incidence of several obesity-associated cancers, particularly endometrial, breast (postmenopausal), and colorectal cancers.

GLP-1 medications produce sustained weight loss of 10–22% of body weight depending on the agent and population. It is biologically plausible — and supported by early epidemiological analyses — that this degree of weight reduction would translate into reduced cancer incidence over a decade or more of follow-up. A 2024 retrospective analysis published in JAMA Oncology found that GLP-1 users had lower rates of 10 out of 13 obesity-associated cancers compared to matched non-users, though the study had limitations inherent to its observational design.

The most important cancer risk calculation for most GLP-1 candidates is not whether semaglutide causes cancer — the evidence says it probably does not — but whether the sustained weight loss it enables reduces the substantial cancer risk that obesity already confers.

What Large Outcomes Studies Tell Us

The SELECT trial represents the most robust cancer safety data available for a GLP-1 agent. With 17,604 participants followed for a median of 3.3 years (and up to 5 years for some), it is powered enough to detect meaningful differences in cancer incidence. No significant increase in any cancer category — thyroid, pancreatic, colorectal, breast, or any other — was observed with semaglutide 2.4 mg versus placebo.

The SURPASS-CVOT trial for tirzepatide is ongoing as of early 2026 and will add to the evidence base for dual GIP/GLP-1 agonists. Early data from the SURMOUNT-4 extension trial showed no malignancy signal at up to 88 weeks of tirzepatide exposure.

Who Actually Has Absolute Contraindications

The following patients must not use GLP-1 medications due to cancer-related contraindications:

• Personal history of medullary thyroid carcinoma (MTC): C-cell origin thyroid cancer, accounting for approximately 3–5% of all thyroid cancers.
• Family history of MTC: Due to the high heritability of MTC via RET proto-oncogene mutations.
• Multiple Endocrine Neoplasia type 2A or 2B (MEN2): Germline RET mutations with very high MTC penetrance.

Prior history of papillary or follicular thyroid cancer, benign thyroid nodules, or a personal history of non-thyroid cancers are not contraindications. Patients with a prior pancreatic cancer history should discuss their specific situation with their oncologist, but there is no FDA contraindication for prior non-pancreatic cancers.

Active Cancer Treatment: A Practical Consideration

For patients currently undergoing cancer treatment, GLP-1 medications are generally paused — not because they are harmful to cancer patients, but because nausea and anorexia from chemotherapy make dosing impractical, and because maintaining nutritional status during treatment takes precedence over weight management. After treatment completion and oncologist clearance, resuming GLP-1 therapy is typically appropriate.

The Bottom Line

Two decades of human pharmacovigilance and large randomized outcomes trials have not confirmed a meaningful cancer risk from GLP-1 medications in the general treatment population. The rodent thyroid C-cell data generated a necessary black box warning and a small group of genuine contraindications — but those findings have not translated to humans. Simultaneously, the emerging evidence that sustained GLP-1-driven weight loss may reduce obesity-associated cancer risk over time means that for most patients, the cancer risk calculation strongly favors treatment.

Sources

• Ozempic (semaglutide) Prescribing Information. Novo Nordisk.
• Wegovy (semaglutide) Prescribing Information. Novo Nordisk.